|
MechanismGlutaminyl-peptide cyclotransferase inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients
This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.
100 Clinical Results associated with Haupt Pharma Wülfing GmbH
0 Patents (Medical) associated with Haupt Pharma Wülfing GmbH
100 Deals associated with Haupt Pharma Wülfing GmbH
100 Translational Medicine associated with Haupt Pharma Wülfing GmbH